Lusaris Therapeutics

Biotech company focused on creating next-gen serotonergic neuroplastogen psychedelic compounds to treat severe neuropsychiatric and neurological conditions Lusaris Therapeutics launched with a $60 million Series A financing.  The round was led by the company’s incubator, RA Capital...